Suppliers / Chongqing Chen'An Biopharmaceutical

Chongqing Chen'An Biopharmaceutical

China Updated 9 July 2026

Chongqing Chen'An Biopharmaceutical is a finished-dose manufacturer based in China. It holds 3 active US drug master files across a filed portfolio of 3 molecules.

3
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Molecule Regulators Docs
Insulin Degludec US FDA 1
Liraglutide US FDA 1
Semaglutide US FDA 1

Also appears on these molecule pages

Questions about Chongqing Chen'An Biopharmaceutical

Does Chongqing Chen'An Biopharmaceutical hold a US DMF or a CEP?
Chongqing Chen'An Biopharmaceutical holds 3 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
What does Chongqing Chen'An Biopharmaceutical make?
3 molecules are on record against Chongqing Chen'An Biopharmaceutical, including Insulin Degludec, Liraglutide and Semaglutide. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Chongqing Chen'An Biopharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability